Original ArticleMetabolic and Receptor Imaging in Patients with Neuroendocrine Tumors: Comparison of Fludeoxyglucose-Positron Emission Tomography and Computed Tomography with Indium in 111 Pentetreotide
Section snippets
INTRODUCTION
Relatively rare neoplasms that arise from neuroendocrine cells, neuroendocrine tumors (NETs) may originate from virtually any organ 1., 2., 3., 4.. Such tumors may secrete hormones that cause distinct syndromes, produce nonspecific symptoms due to mass effect, or remain asymptomatic until incidentally identified. Because NETs are a diverse group of lesions, determining the prognosis associated with a specific NET is often challenging 1., 2., 3., 4.. Clinical variables such as organ of origin,
Study Subjects
Medical records of 522 patients who underwent both PET/CT and indium In 111 pentetreotide imaging at our institution between July 31, 2002, and May 4, 2007, were retrospectively reviewed. Twenty-nine patients were selected who harbored histologically proven NETs and had undergone both indium In 111 pentetreotide and PET/ CT imaging. This retrospective study was reviewed and approved by the Cedars-Sinai Medical Center Institutional Review Board. Patients underwent PET/CT imaging either as part
Clinical Features and Course
The 29 study patients ranged in age from 24 to 78 years (median age, 50) at the time of diagnosis of the NETS (Table 1). Sixteen patients (55%) were male, and 13 (45%) were female. The anatomic sites of the tumors were as follows: pancreas 9 (31%), small bowel 4 (14%), colon 4 (14%), thyroid 4 (14%), lung 1 (3%), and other 7 (24%) (Table 2). Fifteen patients presented with metastatic disease at the time of diagnosis, determined either at surgical intervention or by imaging. One patient each had
DISCUSSION
In this study, we have shown that, among patients with NETs, those with abnormal findings on PET/CT imaging had a generally poorer prognosis and a more rapid clinical deterioration than those with normal findings on PET/CT imaging. Similarly, abnormal findings on pentetreotide imaging trended toward poor clinical outcomes, although these findings were not statistically significant. The numbers are relatively small, but patients with abnormal findings on pentetreotide imaging and normal findings
CONCLUSION
In this study, we have shown that in patients with NETs, abnormalities on PET/CT imaging trend toward an unfavorable prognosis. Pentetreotide imaging may be superior to PET/CT in identification and localization of indolent NETs because PET/CT may not show significant uptake in such tumors. A more formal analysis will be necessary to prove with greater certainty a relationship between PET/CT or pentetreotide uptake (or both) and poor clinical outcomes.
DISCLOSURE
The authors have no conflicts of interest to disclose.
ACKNOWLEDGMENT
Some of the preliminary results of this study were included in an abstract-poster presentation at the annual meeting of the Society of Nuclear Medicine; June 14 to 18, 2008; New Orleans, Louisiana.
REFERENCES (17)
- et al.
Metabolic tumor burden predicts for disease progression and death in lung cancer
Int J Radiat Oncol Biol Phys.
(2007) - et al.
Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose
Int J Radiat Oncol Biol Phys.
(2004) - et al.
Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy
Cancer Treat Rev.
(2008) - et al.
Somatostatin receptor imaging of neuroendocrine tumors with indium- 111 pentetreotide (Octreoscan)
Semin Nucl Med.
(1995) - et al.
Carcinoid tumors
N Engl J Med.
(1999) - et al.
Long-term survival of patients with small intestinal carcinoid tumors
World J Surg.
(2004) Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract
J Surg Oncol.
(2005)- et al.
Neuroendocrine tumours
Endocr Relat Cancer.
(2004)
Cited by (10)
Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, and Pitfalls
2017, Endocrinology and Metabolism Clinics of North AmericaPrognostic Value of <sup>18</sup>F-FDG PET in Neuroendocrine Neoplasm: A Systematic Review and Meta-analysis
2021, Clinical Nuclear MedicineHigh prognostic value of 18f-fdg pet for metastatic gastroenteropancreatic neuroendocrine tumors: A long-term evaluation
2014, Journal of Nuclear Medicine
Published as a Rapid Electronic Article in Press at http://www.endocrinepractice.org on June 2, 2009. DOI: 10.4158/EP08318.ORR1